The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial.
 
Daniel McGrail
No Relationships to Disclose
 
Kaiyi Li
No Relationships to Disclose
 
Allison Nipper
No Relationships to Disclose
 
Faye M. Johnson
Honoraria - Emory University; Methodist Hospital
Research Funding - CUE Biopharma (Inst); PIQUR; Puma Biotechnology (Inst); Takeda; Takeda (Inst); Trovagene; Viracta Therapeutics (Inst)
 
Erison Santana
No Relationships to Disclose
 
Diana Bell
No Relationships to Disclose
 
Minjung Lee
No Relationships to Disclose
 
Cara L Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Nanobiotix
Research Funding - Avenge Bio (Inst); BTG (Inst); Dragonfly Therapeutics (Inst); Iovance Biotherapeutics (Inst); Obsidian Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Adam S. Garden
No Relationships to Disclose
 
Shiaw-Yih Lin
No Relationships to Disclose
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Maura L. Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)
 
Neil D. Gross
Honoraria - American Institute of Continuing Medical Education; OncLive/MJH Life Sciences
Consulting or Advisory Role - Merck; PDS Biotechnology; Regeneron; Replimune
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Merck
 
Andrew G. Sikora
Consulting or Advisory Role - Roche
Research Funding - Celcuity (Inst)
Patents, Royalties, Other Intellectual Property - Patents filed (Inst)
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year